Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Malaria
Malarone Recommended for Prevention and Treatment
December 31st, 2000
The U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, recently changed its recommendation on malaria to include Glaxo Wellcome Inc.'s (GLX) Malarone (atovaquone and proguanil hydrochloride) as another option for the prevention and treatment of malaria. The U.S. Food and Drug Administration (FDA) approved the drug in July 2000. The CDC now recommends Malarone as one of three options for the prevention of Plasmodium falciparum malaria, including those infections acquired in areas with chloroquine-resistant strains. The CDC also recommends Malarone as an option for the treatment of uncomplicated P. falciparum...
Source: Medical Letter on the CDC & FDA (2000-12-31)
|
